NCT04720976

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Completed Phase 1, PHASE2 Last updated 11 April 2025

What this trial tests

Phase 1, PHASE2 trial testing JAB-3312 in Solid Tumor in 58 participants. Completed in 19 December 2023.

Timeline

23 March 2021

Primary endpoint
19 December 2023

19 December 2023

Quick facts

Lead sponsor	Allist Pharmaceuticals, Inc.
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	58
Start date	23 March 2021
Primary completion	19 December 2023
Estimated completion	19 December 2023
Sites	15 locations across United States

Drugs / interventions tested

• JAB-3312
• Binimetinib (binimetinib) — full drug profile →
• Pembrolizumab (pembrolizumab) — full drug profile →
• Sotorasib (SOTORASIB) — full drug profile →
• Osimertinib (osimertinib) — full drug profile →

Conditions studied

• Solid Tumor — all drugs for Solid Tumor →
• NSCLC — all drugs for NSCLC →

Sponsor

Allist Pharmaceuticals, Inc. — full company profile →

Who can join

18 and older, any sex, with Solid Tumor or NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. The current state of the art and future trends in RAS-targeted cancer therapies.
   Punekar SR, Velcheti V, Neel BG, Wong KK. · · 2022 · cited 382× · PMID 36028717 · DOI 10.1038/s41571-022-00671-9
2. Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.
   Hofmann MH, Gerlach D, Misale S, Petronczki M, et al · · 2022 · cited 247× · PMID 35046095 · DOI 10.1158/2159-8290.cd-21-1331
3. Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.
   Xie X, Yu T, Li X, Zhang N, et al · · 2023 · cited 246× · PMID 37669923 · DOI 10.1038/s41392-023-01589-z
4. Targeting KRAS in pancreatic cancer: new drugs on the horizon.
   Bannoura SF, Uddin MH, Nagasaka M, Fazili F, et al · · 2021 · cited 81× · PMID 34499267 · DOI 10.1007/s10555-021-09990-2
5. Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders.
   Stanford SM, Bottini N. · · 2023 · cited 80× · PMID 36693907 · DOI 10.1038/s41573-022-00618-w
6. SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment.
   Sodir NM, Pathria G, Adamkewicz JI, Kelley EH, et al · · 2023 · cited 69× · PMID 37682219 · DOI 10.1158/2159-8290.cd-23-0383
7. Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes.
   Palma G, Khurshid F, Lu K, Woodward B, et al · · 2021 · cited 49× · PMID 34845311 · DOI 10.1038/s41698-021-00237-5
8. MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.
   Casacuberta-Serra S, González-Larreategui Í, Capitán-Leo D, Soucek L. · · 2024 · cited 43× · PMID 39164274 · DOI 10.1038/s41392-024-01907-z